Innate Pharma SA Class A · EURONEXT:IPH
Innate Pharma SA Class A — Technical Presentation (November 2026)
32 slides from Innate Pharma SA Class A's technical presentation, Nov 18, 2026
Slide 1: IPH4502: A Novel And Differentiated Nectin-4 ADC
KOL Event For Investors And Analysts IPH4502: A Novel And Differentiated Nectin-4 ADC Phase 1 Clinical Data And Development Outlook November 18, 2026 | London
Slide 2: Disclaimer on forward-looking information and risk factors
Disclaimer on forward-looking information and risk factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains certai
Slide 3: Agenda
Agenda Jonathan DICKINSON, MBA, BSc Chief Executive Officer Introduction and pipeline overview Yannis MOREL, PhD Chief Operating Officer IPH4502 scientific rationale Professor Yohann LORIOT, MD, PhD Advanced Urothelial Cancer Treatment Landscape Gustave Roussy Investigator in the IPH4502-101 study a
Slide 4: Professor Yohann Loriot, M.D., Ph.D.
Professor Yohann Loriot, M.D., Ph.D. Medical oncologist specializing in urothelial cancer Gustave Roussy Deputy Head, Therapeutic Innovation and Early Trials Professor, Paris-Saclay University Lead, EORTC Urological Tumours Study Group INVESTIGATOR IN THE IPH4502-101 STUDY Disclosures Professor Yoha
Slide 5: Introduction and Pipeline Overview
INTRODUCTION AND PIPELINE OVERVIEW Jonathan Dickinson, CEO 5
Slide 6: Pipeline Overview
Pipeline Overview PROGRAM Target Status Preclinical Phase 1 Phase 2 Phase 3 Projected next steps PROPRIETARY PIPELINE · ADCs IPH4502 ADC Proprietary Dose optimization Advanced solid tumors Anti-Nectin-4 Next Gen ADCs Undisclosed Proprietary Candidate selection Built on proprietary linker PARTNERED P
Slide 7: IPH4502 Phase 1 Key Findings
IPH4502 IPH4502 Phase 1 Key Findings • Well-tolerated through dose-escalation — Low overall hematologic toxicity, consistent with low circulating free-exatecan levels, which support linker stability — Stomatitis observed as the only DLT with MTD at 3.6 mg/kg Q3W. Stomatitis is common with some topo-
Slide 8: IPH4502: a differentiated Nectin-4 Topo I ADC positioned in UC post-EV
IPH4502: a differentiated Nectin-4 Topo I ADC positioned in UC post-EV NECTIN-4 ADCs LANDSCAPE NECTIN-4 ADCs IN UC POST-EV Phase / Asset / Company Region Key indications EV (PADCEV) established MMAE ADCs LY4052031 Established signal for Nectin-4 commercial opportunity Eli Lilly Topo I ADC after in U
Slide 9: IPH4502 Scientific Rationale
IPH4502 SCIENTIFIC RATIONALE Yannis Morel, COO 9
Slide 10: IPH4502 Design Rationale And Potential Points Of Clinical Differentiation
IPH4502 Design Rationale And Potential Points Of Clinical Differentiation KEY DESIGN FEATURES & POTENTIAL CLINICAL POTENTIAL BENEFITS DIFFERENTIATORS • Low susceptibility to MDR1 efflux pump To deliver activity in UC post-EV EXATECAN to help overcome resistance to EV PAYLOAD (bypassing MMAE resistan
Slide 11: Advanced UC Treatment Landscape and Phase 1 IPH4502 Clinical Findings
ADVANCED UC TREATMENT LANDSCAPE AND PHASE 1 IPH4502 CLINICAL FINDINGS Yohann Loriot, MD, PhD 11
Slide 12: Beyond 1L EV+P: Addressing Progression and Treatment Discontinuation
Beyond 1L EV+P: Addressing Progression and Treatment Discontinuation EV+P FRONTLINE STANDARD IN UC POST-EV+P EFFICACY¹ No established SoC post-EV ORR 67.5% (95% CI 62.9–71.9) mDoR ~70% received Platinum-based ~2 years chemotherapy² among patients receiving subsequent systemic therapy ~50% of respond
Slide 13: IPH4502-101: Study Design, Eligibility Criteria, Objectives
IPH4502-101: Study Design, Eligibility Criteria, Objectives A Phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors (NCT06781983) Dose Escalation (N=76 patients) Key Eligibility • Study: BOIN design with backfilling Ke
Slide 14: IPH4502-101: Patient Demographics And Baseline Characteristics
IPH4502-101: Patient Demographics And Baseline Characteristics All patients UC patients (N=76) (n=19) Median age, years (range) 63 (30 - 78) 64 (40 - 77) Sex, n (%) • Heavily pre-treated patients with a Female 23 (30.3) 3 (15.8) median of 3.5 prior lines of systemic Male 53 (69.7) 16 (84.2) ECOG PS,
Slide 15: IPH4502-101: Tumor Types And Patient Distribution Across Dose Levels
IPH4502-101: Tumor Types And Patient Distribution Across Dose Levels Dose level (mg/kg) 0.6 1.2 2.4 2.8 3.2 3.6 UC post EV (n=19) • Phase 1 signal seeking in more than 10 tumor types HNSCC (n=18) CRC (n=9) • Most UC patients were enrolled at Ovarian (n=5) intermediate dose levels TNBC (n=5) • 15 at
Slide 16: IPH4502-101: Well Tolerated To Date, Stomatitis As The Only Reported DLT
IPH4502-101: Well Tolerated To Date, Stomatitis As The Only Reported DLT MTD: 3.6 mg/kg, with stomatitis as the TEAEs SUMMARY – patients, n (%) only DLT TEAEs Occurring in ≥10% of Patients Any TEAE 73 (96.1%) Grade ≥3 TEAEs 33 (43.4%) Low hematologic toxicity TEAEs leading to dose reduction 6 (7.9%)
Slide 17: IPH4502-101: Antitumor Activity Across Several Dose Levels And Tumor Types
IPH4502-101: Antitumor Activity Across Several Dose Levels And Tumor Types Dose 0.6 1.2 2.4 2.8 3.2 3.6 (mg/kg) UC post-EV Other ORR1 (%) 0% 0% 11% 4% 17% (22%)2 33% Nectin-4 H-Score Prior Topo I ADC Tumor Type Nectin-4 H-Score Prior Topo I ADC Tumor Type (15 participants ongoing at DCO) IPH4502 is
Slide 18: IPH4502-101: Antitumor Activity Observed Across Nectin-4 Expression Levels
IPH4502-101: Antitumor Activity Observed Across Nectin-4 Expression Levels Nectin-4 Low Nectin-4 Moderate Nectin-4 High H-score = 60 H-score = 190 H-score = 300 HNSCC, male patient, 78 years NSCLC, male patient, 72 years Cervical cancer, female patient, 63 years Target lesion change1 - 33.5% - 44.7%
Slide 19: IPH4502-101: Low Free Exatecan Levels Consistent With Low Hematologic Toxicity
IPH4502-101: Low Free Exatecan Levels Are Consistent With Low Hematologic Toxicity Plasma concentration at 3.6 mg/kg (cycle 1, n=6) 1000 • Low systemic free-exatecan levels • Slow payload release Analyte concentration (nM) 100 Free-exatecan Cmax at D2-D3 10 1 Low free exatecan levels are consistent
Slide 20: IPH4502-101 Summary
IPH4502-101 Summary • 76 heavily pretreated patients (Median 3.5 prior lines) • 6 dose levels: 0.6-3.6 mg/kg Q3W across more than 10 tumor types Population • No Nectin-4 preselection (31% negative, 26% low, 12% moderate and 31% high – n=65) • UC patients (n=19) received prior EV. Most UC patients en
Slide 21: Next Step: Dose Optimization
NEXT STEP: DOSE OPTIMIZATION Markus Jensen, CMO 21
Slide 22: IPH4502: Emerging clinical observations and potential differentiators
IPH4502: Emerging clinical observations and potential differentiators KEY DESIGN FEATURES IPH4502-101 Ph1 OBSERVATIONS • Low susceptibility to MDR1 efflux pump EXATECAN to help overcome resistance to EV Objective responses observed in UC post-EV PAYLOAD • Strong bystander killing DAR8 patients • Met
Slide 23: IPH4502-101: PK Findings Support Exploring Split Dosing
IPH4502-101: PK Findings Support Exploring Split Dosing IPH4502 Area Under the Curve Dose Normalized (AUC/D) Higher exposure at 3.6 mg/kg The increase in IPH4502 AUC Dose normalized at 3.6 mg/kg versus 3.2 mg/kg may be consistent with Nectin-4 saturation Split-dose exploration These PK findings supp
Slide 24: Split Dosing
Split Dosing Limits High Peak Concentrations While Aiming To Maintain Tumor Exposure To ADC Dose divided across D1 & D8 of each 3-week cycle (Q3W) Several approved ADCs with split dose regimens • Padcev® D1, D8, D15 every 4W • Trodelvy® D1, D8 Q3W • Iza-bren* D1, D8 Q3W Illustrative* * Schematic ill
Slide 25: IPH4502 Next Steps: Dose Optimization In UC Post EV
IPH4502 Next Steps: Dose Optimization In UC Post EV PHASE 1 DOSE ESCALATION PHASE 1 DOSE OPTIMIZATION COMPLETED • Day 1, every 3 weeks • Split dose* day 1 and day 8, every 3 weeks Dose and • MTD = 3.6 mg/kg with stomatitis as DLT • To widen therapeutic window and reduce stomatitis** schedule • ORR
Slide 26: IPH4502 Projected Development Timeline
IPH4502 Projected Development Timeline 2027-2028 2028 onwards Dose optimization in UC post-EV Phase 2/3 in UC post-EV Determine the RP2D Additional development opportunities • Earlier line of therapy in UC (IO combinations) • Explore emerging activity signals in other tumor types with low or heterog
Slide 27: Closing Remarks and Q&A Discussion
CLOSING REMARKS AND Q&A DISCUSSION Jonathan Dickinson, CEO 27
Slide 28: IPH4502 Phase 1 Key Findings
IPH4502 IPH4502 Phase 1 Key Findings • Well-tolerated through dose-escalation — Low overall hematologic toxicity, consistent with low circulating free-exatecan levels, which support linker stability — Stomatitis observed as the only DLT with MTD at 3.6 mg/kg Q3W. Stomatitis is common with some topo-
Slide 29: Thank You
Thank You www.innate-pharma.com info@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA
Slide 30: IPH4502-101: Treatment-emergent adverse events ≥10% (all participants)
APPENDIX IPH4502-101: Treatment-emergent adverse events ≥10% (all participants) Overall 0.6 MG/KG 1.2 MG/KG 2.4 MG/KG 2.8 MG/KG 3.2 MG/KG 3.6 MG/KG (N=76); n (%) (N=3); n (%) (N=7); n (%) (N=18); n (%) (N=24); n (%) (N=18); n (%) (N=6); n (%) All All All All All All All ≥ G3 ≥ G3 ≥ G3 ≥ G3 ≥ G3 ≥ G3
Slide 31: Clinical Examples From Other ADCs Split dosing: BHV-1510 case study
APPENDIX Clinical Examples From Other ADCs Split dosing: BHV-1510 case study BHV-1510 (TROP2 ADC) + cemiplimab 1 Phase 1, n=31 BHV-1510: Site-specific DAR4 TROP-2 ADC with a Stomatitis AE (%) novel Topo I payload (TopoIx) Stomatitis data extracted from the Phase 1 study: Q3W (2-2.75 mg/kg) 22.7% 59.
Slide 32: Clinical Examples From Other ADCs Split dosing: Iza-Bren case study
APPENDIX Clinical Examples From Other ADCs Split dosing: Iza-Bren case study Iza-Bren (EGFR x HER3 ADC – Phase 1)1 Iza-Bren - Phase 1 Q3W (5 mg/kg) 34.8% ORR (%) Iza-Bren: First-in-class bispecific EGFR × D1, D8 Q3W HER3 ADC (2.5 mg/kg) 30.9% 0 10 20 30 40 Antitumor activity data extracted from two
Innate Pharma — Technical Presentation (November 2026) on 6ix